However, cancer cells often respond to TGF-β by stimulating the expression of matrix-degrading enzymes, thus contributing to ECM degradation and invasiveness through epithelial-to-mesenchymal transition (EMT) 27. The gene discussed is TGFB1; the disease is cancer.